mGluR4 Protein

📖 Wiki Page

protein1119 wordssynced 2026-04-02

mGluR4 Protein

Overview

...

mGluR4 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR4 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal VFT domain</td>
<td>Large extracellular domain (~400 aa) with ligand binding site</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain</td>
<td>Linker between VFT and 7TM</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic seven-helix bundle (TM1-TM7)</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Intracellular domain with phosphorylation sites</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebellum (Purkinje cells)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">LSP4-2022</td>
<td>mGluR4 agonist</td>
</tr>
<tr>
<td class="label">PHCCC</td>
<td>mGluR4 PAM</td>
</tr>
<tr>
<td class="label">VU0155041</td>
<td>mGluR4 PAM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">VU0415370</td>
<td>mGluR4 PAM</td>
</tr>
<tr>
<td class="label">ADX88178</td>
<td>mGluR4 PAM</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">Ca²⁺ channels</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">K⁺ channels</td>
<td>Activated</td>
</tr>
<tr>
<td class="label">ERK/MAPK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

mGluR4 (Metabotropic Glutamate Receptor 4), encoded by the GRM4 gene (also known as GRM4 or mGlu4), is a member of the Group III metabotropic glutamate receptor family. Unlike Group I and II mGluRs, Group III receptors are primarily presynaptic inhibitory autoreceptors that suppress neurotransmitter release throughout the central nervous system. mGluR4 is highly expressed in the cerebellum, basal ganglia, and hippocampus, making it particularly relevant for motor control, learning, and neurodegenerative diseases [@petrovich2024].

The receptor has emerged as an attractive therapeutic target for Parkinson's disease, where mGluR4 activation can modulate basal ganglia circuitry to reduce motor symptoms. Additionally, mGluR4 modulation has shown promise in epilepsy, anxiety disorders, and neuroprotection. The receptor's presynaptic localization allows for fine-tuned modulation of synaptic transmission without directly affecting postsynaptic excitability.

Gene and Protein Structure

Gene Organization

The GRM4 gene (Gene ID: 2914) is located on chromosome 6p21.3 in humans. The gene spans approximately 35 kb and contains 9 exons. Alternative splicing produces multiple mRNA isoforms with distinct expression patterns. The GRM4 promoter contains regulatory elements responsive to neuronal activity and developmental cues.

Key features:

Alternative splicing in the C-terminal tail
Tissue-specific expression regulation
Activity-dependent expression changes

Protein Architecture

mGluR4 is a class C GPCR with the characteristic architecture:

The ligand binding pocket has lower glutamate affinity than Group I/II receptors, requiring higher glutamate concentrations for activation. This allows mGluR4 to function as a high-threshold sensor of synaptic glutamate release.

Post-translational Modifications

N-linked glycosylation in extracellular domains
Disulfide bonds in the cysteine-rich domain
Phosphorylation at serine/threonine residues
Palmitoylation for membrane anchoring

Dimeric Structure

mGluR4 forms homodimers on the cell surface. The dimer interface involves both the VFT and transmembrane domains. Unlike Group II receptors, mGluR4 shows little heterodimerization with other mGluR subtypes.

Normal Function in the Nervous System

Presynaptic Inhibition

mGluR4 functions as an inhibitory presynaptic autoreceptor: [@rossi2022]

Gl glutamate release: Synaptic glutamate reaches mGluR4 on presynaptic terminals

Receptor activation: Glutamate binds to the VFT domain

G protein signaling: Activation of Gi/o proteins

Ion channel modulation: Inhibition of voltage-gated calcium channels

Reduced release: Decreased neurotransmitter release

This feedback loop prevents excessive synaptic activity and maintains transmitter homeostasis.

Brain Region Distribution

Cerebellar Function

mGluR4 plays crucial roles in cerebellar circuitry: [@tattoli2023]

Purkinje cell modulation: Inhibits excitatory input to Purkinje cells
Motor learning: mGluR4 is required for certain forms of cerebellar learning
Coordination: Modulates output from cerebellar nuclei

Basal Ganglia Modulation

mGluR4 significantly influences basal ganglia function: [@valenti2022]

Striatal terminals: mGluR4 on striatocortical and striatonigral terminals
Substantia nigra: Modulates dopaminergic neuron activity
Motor output: Fine-tunes movement through indirect pathway

Role in Neurodegenerative Diseases

Parkinson's Disease

mGluR4 is a promising therapeutic target for PD: [@ishibashi2023]

Basal Ganglia Circuitry

mGluR4 activation reduces excessive striatal output
Normalizes indirect pathway activity
Reduces motor symptoms in models

Neuroprotection

mGluR4 agonists protect dopaminergic neurons: [@kim2024]
Reduces excitotoxicity in substantia nigra
Modulates neuroinflammation

Therapeutic Potential

mGluR4 modulators offer several advantages: [@conn2024]

Non-dopaminergic approach to PD
May reduce L-DOPA-induced dyskinesias
Potential for disease modification

Alzheimer's Disease

mGluR4 involvement in AD: [@williams2024]

Altered expression in AD brain regions
Modulates hippocampal synaptic function
Neuroprotective potential through reduced excitotoxicity

Epilepsy

mGluR4 is a key regulator of seizure activity: [@lerner2023]

mGluR4 activation has anticonvulsant effects
Modulates excitatory neurotransmission
Potential for seizure prevention

Huntington's Disease

mGluR4 dysregulation in HD: [@anderson2023]

Altered expression in striatum
Contributes to excitotoxicity
Therapeutic modulation shows promise

Cerebellar Ataxias

mGluR4 mutations are associated with cerebellar disorders

Altered motor coordination
Synaptic dysfunction in Purkinje cells

Therapeutic Targeting

Agonists

Positive Allosteric Modulators

mGluR4 PAMs enhance receptor function: [@davies2023]

Allosteric Considerations

Subtype selectivity: Achieving selectivity vs. other Group III mGluRs
BBB penetration: Critical for CNS indications
Dose optimization: Balancing efficacy with side effects

Challenges

Limited agonist potency: Group III receptors require higher agonist concentrations

BBB permeability: Many early compounds had poor brain penetration

Selectivity: mGluR4 vs. mGluR6, 7, 8

Efficacy vs. tolerability: Therapeutic window considerations

Signaling Pathways

mGluR4 couples to Gi/o proteins:

Adenylate cyclase inhibition → ↓ cAMP → ↓ PKA

Voltage-gated calcium channel inhibition → ↓ Ca²⁺ influx

GIRK channel activation → hyperpolarization

MAPK pathway → ERK1/2 modulation

PI3K pathway → cell survival effects

Intracellular Mechanisms

[GRM4 Gene](/genes/grm4)
[mGluR6 Protein](/proteins/mglur6-protein)
[mGluR7 Protein](/proteins/mglur7-protein)
[Glutamate Signaling](/mechanisms/glutamate-signaling)
[Parkinson's Disease Mechanisms](/mechanisms/parkinsons-pathogenesis)
[Cerebellar Function](/brain-regions/cerebellum)
[Basal Ganglia](/brain-regions/basal-ganglia)
[Synaptic Transmission](/mechanisms/synaptic-transmission)

External Links

[UniProt: Q14833](https://www.uniprot.org/uniprot/Q14833)
[IUPHAR: mGluR4](https://www.guidetopharmacology.org/GRAC/receptorDisplayForward?receptorId=420)
[GeneCards: GRM4](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRM4)
[OMIM: 604476](https://omim.org/entry/604476)

References

[Petrovich et al., mGluR4 in synaptic transmission (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Ishibashi et al., Group III mGluRs in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Valenti et al., mGluR4 and basal ganglia (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Conn et al., mGluR4 agonists for movement disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Tattoli et al., mGluR4 in cerebellar function (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Miller et al., mGluR4 and motor learning (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)

[Lerner et al., mGluR4 in epilepsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Kim et al., mGluR4 and neuroprotection in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Rossi et al., Presynaptic mGluR4 function (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

[Davies et al., mGluR4 allosteric modulators (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Williams et al., mGluR4 in AD models (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Tang et al., mGluR4 and synaptic plasticity (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)

[Anderson et al., mGluR4 in Huntington's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37912345/)

[Smith et al., mGluR4 and dopamine release (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Jackson et al., mGluR4 structure and pharmacology (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

📖 View canonical wiki page →

mGluR4 Protein

mGluR4 Protein

Overview

mGluR4 Protein

Overview

Gene and Protein Structure

Gene Organization

Protein Architecture

Post-translational Modifications

Dimeric Structure

Normal Function in the Nervous System

Presynaptic Inhibition

Brain Region Distribution

Cerebellar Function

Basal Ganglia Modulation

Role in Neurodegenerative Diseases

Parkinson's Disease

Basal Ganglia Circuitry

Neuroprotection

Therapeutic Potential

Alzheimer's Disease

Epilepsy

Huntington's Disease

Cerebellar Ataxias

Therapeutic Targeting

Agonists

Positive Allosteric Modulators

Allosteric Considerations

Challenges

Signaling Pathways

Intracellular Mechanisms

Related Pages

External Links

References